WHITE BEAR LAKE, Minnesota, June 30, 2026
Envoy Medical announced the submission of the first module of its Modular Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for its Breakthrough Device-designated Acclaim® cochlear implant. The filing marks the company’s first formal regulatory milestone under a modular review strategy that allows completed sections of the PMA application to be submitted individually, enabling the FDA to begin reviewing nonclinical and manufacturing data while the pivotal clinical trial remains ongoing. Envoy plans to submit a total of four PMA modules, with the final clinical module targeted for the second quarter of 2027. The company believes the approach will create a structured regulatory roadmap, improve development visibility, and support earlier interaction with the FDA throughout the review process.
Modular PMA Strategy Enables Earlier FDA Collaboration
Unlike a traditional PMA submission, which requires all documentation to be filed simultaneously, the modular PMA pathway permits staged submissions as individual sections are completed. Envoy Medical said this strategy enables continuous FDA engagement, allowing regulatory feedback on manufacturing, nonclinical, and technical documentation before final clinical data become available. Company executives believe this phased approach reduces execution risk by identifying potential issues earlier while establishing measurable development milestones throughout the regulatory process. The strategy also aligns with the enhanced communication opportunities available under the FDA’s Breakthrough Device Program.
Breakthrough Device Program Supports Regulatory Progress
Envoy Medical’s investigational Acclaim® cochlear implant received FDA Breakthrough Device Designation in 2019 and is currently being evaluated in a U.S.-based pivotal clinical trial. The designation is intended to accelerate the development and review of medical devices that may provide more effective treatment for life-threatening or irreversibly debilitating conditions. According to the company, the modular PMA framework complements the Breakthrough Device pathway by facilitating ongoing regulatory collaboration while clinical development continues. Management expects to submit four PMA modules over the next year, culminating with final clinical trial data in Q2 2027.
Advertisement
Company Advances Fully Implanted Hearing Technology
Envoy Medical develops fully implanted hearing technologies designed to improve patient convenience and long-term hearing outcomes. In addition to its investigational Acclaim® cochlear implant, the company markets the fully implanted Esteem® active middle ear implant, which has been commercially available in the United States since 2010. The company stated that its Invisible Hearing® technology platform is intended to improve usability, treatment compliance, and quality of life for patients with hearing loss. By pursuing the modular PMA pathway, Envoy aims to accelerate regulatory review while providing investors and stakeholders with greater transparency into its progress toward potential FDA approval.
Source:Envoy Medical press release
